CN103408593A - Preparation method of tenofovir - Google Patents
Preparation method of tenofovir Download PDFInfo
- Publication number
- CN103408593A CN103408593A CN2013102918831A CN201310291883A CN103408593A CN 103408593 A CN103408593 A CN 103408593A CN 2013102918831 A CN2013102918831 A CN 2013102918831A CN 201310291883 A CN201310291883 A CN 201310291883A CN 103408593 A CN103408593 A CN 103408593A
- Authority
- CN
- China
- Prior art keywords
- preparation
- tynofovir
- nitro
- reaction
- chloropyrimide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title abstract description 8
- 229960004556 tenofovir Drugs 0.000 title abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 10
- RUOJZAUFBMNUDX-GSVOUGTGSA-N (4r)-4-methyl-1,3-dioxolan-2-one Chemical compound C[C@@H]1COC(=O)O1 RUOJZAUFBMNUDX-GSVOUGTGSA-N 0.000 claims abstract description 9
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 6
- 238000005915 ammonolysis reaction Methods 0.000 claims abstract description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 5
- 238000006482 condensation reaction Methods 0.000 claims description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 6
- 125000003368 amide group Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- -1 methyl-formiate Chemical compound 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 229910052728 basic metal Inorganic materials 0.000 claims description 4
- 150000003818 basic metals Chemical class 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 2
- 238000004904 shortening Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 13
- 230000005494 condensation Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000009833 condensation Methods 0.000 abstract description 2
- BWLOHIMQWHFSQF-UHFFFAOYSA-N 6-chloro-5-nitropyrimidin-4-amine Chemical compound NC1=NC=NC(Cl)=C1[N+]([O-])=O BWLOHIMQWHFSQF-UHFFFAOYSA-N 0.000 abstract 2
- CEXCTVLIYVFPCN-SCSAIBSYSA-N (2R)-1-[(6-chloro-5-nitropyrimidin-4-yl)amino]propan-2-ol Chemical compound O[C@@H](CNC1=NC=NC(=C1[N+](=O)[O-])Cl)C CEXCTVLIYVFPCN-SCSAIBSYSA-N 0.000 abstract 1
- MJZYTEBKXLVLMY-RXMQYKEDSA-N (2r)-1-(6-aminopurin-9-yl)propan-2-ol Chemical compound N1=CN=C2N(C[C@H](O)C)C=NC2=C1N MJZYTEBKXLVLMY-RXMQYKEDSA-N 0.000 abstract 1
- LVNBNKMMTVWRJO-RXMQYKEDSA-N (2r)-1-(6-chloropurin-9-yl)propan-2-ol Chemical compound N1=CN=C2N(C[C@H](O)C)C=NC2=C1Cl LVNBNKMMTVWRJO-RXMQYKEDSA-N 0.000 abstract 1
- 238000006266 etherification reaction Methods 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000007142 ring opening reaction Methods 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 229960001355 tenofovir disoproxil Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 4
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- VZIQXGLTRZLBEX-UHFFFAOYSA-N 2-chloro-1-propanol Chemical compound CC(Cl)CO VZIQXGLTRZLBEX-UHFFFAOYSA-N 0.000 description 1
- 0 C[C@](*)C[n]1c2ncnc(N)c2nc1 Chemical compound C[C@](*)C[n]1c2ncnc(N)c2nc1 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- GOOHAUXETOMSMM-GSVOUGTGSA-N R-propylene oxide Chemical compound C[C@@H]1CO1 GOOHAUXETOMSMM-GSVOUGTGSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical class N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a preparation method of tenofovir (I), which comprises the following steps: carrying out ring opening condensation on a raw material 4-amino-5-nitro-6-chloropyrimidine (II) with (R)-propylene carbonate to generate (R)-4-[N-(2-hydroxypropyl)amino]-5-nitro-6-chloropyrimidine (III), carrying out reduction cyclization on the intermediate (III) to generate (R)-1-(6-chloropurine-9-yl)-2-propanol (IV), carrying out ammonolysis on the intermediate (IV) to generate (R)-1-(6-aminopurine-9-yl)-2-propanol (V), and carrying out etherification and hydrolysis reaction on the intermediate (V) to obtain the tenofovir (I). The preparation method has the advantages of accessible raw materials, simple technique and fewer side reactions, and is suitable for industrial production.
Description
Technical field
The invention belongs to organic synthetic route design and bulk drug thereof and intermediate preparing technical field, particularly a kind of preparation method of tynofovir.
Background technology
Tenofovir disoproxil fumarate (Tenofovir disoproxil fumarate, Tenofovir, TDF) be the new drug that is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection by the research and development of U.S.'s gill moral (Gilead Sciences) company.In calendar year 2001, get permission the listing in the U.S., commodity are called Wei Ruide (Viread).The whole world is existing comprise China surpass the treatment of 100 state approval tynofovirs for acquired immune deficiency syndrome (AIDS).In addition, 2008 FDA (Food and Drug Adminstration) (FDA) ratified the new indication that tenofovir disoproxil is used for the treatment of chronic hepatitis B.At present, there have been more than 30 countries and regions to obtain the approval of this novel indication.The Clinical Trials of Chinese food Drug Administration (SFDA) approval tenofovir disoproxil treatment chronic hepatitis B in 2011, this medicine, in Chinese registration and approval, will bring new treatment to Chinese Chronic Hepatitis B to select.
Tenofovir disoproxil is the acyclic nucleotide phosphodiester analogue of AMP, belongs to the ucleotides reverse transcriptase inhibitors.Tynofovir is prodrug, and chemical name is: (R)-9-(2-phosphate methoxy propyl group) VITAMIN B4.
No. US5935946th, the former United States Patent (USP) ground of gill moral company with reported for No. US5922695 with VITAMIN B4 with the S-Racemic glycidol through catalytic hydrogenation, become the reactions such as ring coupling and esterification catalysis to make tenofovir disoproxil.Introducing for chiral hydroxyl group, Chinese patent No. CN102899367, No. CN102863445, No. CN102295660, No. CN101906119 and No. CN101648974 etc. have been reported with chirality propylene chlorohydrin, (R)-propylene oxide, (R)-lactate and (R)-1, the 2-propylene glycol is raw material, with VITAMIN B4 generation condensation reaction, generates respectively the method for (R)-1-(adenine-9-yl)-2-propyl alcohol (V).Chinese patent has reported that take (R)-propylene carbonate generates the method for intermediate (V) as raw material and VITAMIN B4 condensation for No. CN102060876 and No. CN101870713.In addition, more research report is also arranged in the guard method of the sequencing of condensation, esterification and hydrolysis reaction and the functional groups such as amino, hydroxyl.
In sum, although it is varied to prepare the method for tynofovir and ester, its parent nucleus raw material is VITAMIN B4.Thereby when condensation reaction occurs, or need to be by amido protecting, or need to strengthen by different catalyzer the selectivity of its reaction.So existing technique general steps is more, and difficult quality is controlled." Organic Process Research& Development " 2010 years, the 14th phase, multiple existing its preparation process has been reported in the research of 1194-1201 page, point out to have now and take VITAMIN B4 in the synthesis process of starting raw material, when generating intermediate (R)-1-(adenine-9-yl)-2-propyl alcohol (V), also can produce to some extent process contaminants (VI) and (VII).
Summary of the invention
In order to overcome defect of the prior art, the present invention is according to the synthetic theory of Green Chemistry, a kind of preparation method of novel tynofovir (I) is provided, the characteristics such as this preparation method has that raw material is easy to get, technique is succinct, cost is lower and quality controllable, so be beneficial to the suitability for industrialized production of this bulk drug, promote the development of its economic technology.
To achieve these goals, main technical schemes provided by the present invention is as follows: the preparation method of a kind of tynofovir (I),
Described preparation method, its preparation process comprises: the 4-amino-5-nitro-6-chloropyrimide (II) of take is raw material, with (R)-propylene carbonate, carry out open loop condensation reaction generation (R)-4-[N-(2-hydroxypropyl) amido]-5-nitro-6-chloropyrimide (III), intermediate (III) generates (R)-1-(6-chloropurine-9-yl)-2-propyl alcohol (IV) through the reductive ring closure reaction, intermediate (IV) generates (R)-1-(adenine-9-yl)-2-propyl alcohol (V) through ammonolysis reaction, and intermediate (V) makes tynofovir (I) through etherificate and hydrolysis reaction.
In addition, the present invention also comprises following attached technical scheme:
The molar ratio that described 4-amino-5-nitro-6-chloropyrimide (II) and (R)-propylene carbonate carry out the open loop condensation reaction is 1: 0.85-2.0, preferably 1: 1.1-1.5.
The promotor of the open loop condensation reaction of described 4-amino-5-nitro-6-chloropyrimide (II) and (R)-propylene carbonate is hydride, alkali-metal carbonate, alkali-metal supercarbonate or the alkali alcoholate of metal on oxyhydroxide, basic metal or the alkali of metal on basic metal or alkali, preferably sodium hydride, potassium tert.-butoxide or tert-butyl alcohol magnesium.
The reductive agent of described reduction reaction is zinc powder, iron powder, vat powder, hydrazine hydrate or shortening, preferably zinc powder or vat powder.
The cyclizing agent of described ring-closure reaction is formic acid, methyl-formiate, ethyl formate or methane amide, preferable formic acid.
The ammoniation agent of described ammonolysis reaction is ammoniacal liquor or liquefied ammonia.
Than prior art, the preparation method of tynofovir involved in the present invention, have that raw material is easy to get, technique is succinct, cost is lower and the characteristics such as quality controllable, so be beneficial to the suitability for industrialized production of this bulk drug, promotes the development of its economic technology.
Embodiment
Below in conjunction with several preferred embodiments, technical solution of the present invention is done to further nonrestrictive detailed description, wherein by (R)-1-(adenine-9-yl)-2-propyl alcohol (V), making the process of tynofovir (I) through etherificate and hydrolysis reaction can be with reference to the method for " Drugs of the Future " 1998, the 23rd 12 phase of volume 1279-1286 page.
Embodiment mono-:
In reaction flask, add 4-amino-5-nitro-6-chloropyrimide (II) (1.73g, 10mmol) and DMF 20mL, stirring at room is to dissolving.Be cooled to 0-5 ℃, add potassium tert.-butoxide (2.8g, 2.5eq) in batches, drip simultaneously (R)-propylene carbonate (1.33g, 13mmol).Slowly rise to room temperature, stirred 5～7 hours.Add toluene, decrease temperature crystalline, filter.Filter cake obtains off-white color solid (R)-4-[N-(2-hydroxypropyl) amido with ethyl alcohol recrystallization]-5-nitro-6-chloropyrimide (III) 2.0g, yield is 85.8%.
Embodiment bis-:
In reaction flask, add (R)-4-[N-(2-hydroxypropyl) amido]-5-nitro-6-chloropyrimide (III) (2.32g, 10mmol), vat powder (4.35g, 2.5eq), methyl alcohol 25mL and distilled water 25mL, be warming up to 50-60 ℃, stirring reaction 6 hours.Be evaporated to volume half, with dichloromethane extraction 3 times.Merge organic phase, washing, be concentrated into dryly, adds formic acid 25mL, is warming up to 150-170 ℃, insulation reaction 3 hours.Add activated carbon decolorizing, concentrated, with solid, to separate out, water and methyl alcohol making beating rinsing, filter, and obtains faint yellow solid (R)-1-(6-chloropurine-9-yl)-2-propyl alcohol (IV) 1.7g, and yield is 80.2%.
Embodiment tri-:
In reaction flask, add (R)-1-(6-chloropurine-9-yl)-2-propyl alcohol (IV) (1.1g, 5mmol) and saturated ammonia methanol solution 50mL, sealing stirring reaction 16 hours.Be evaporated to dry.With the distilled water recrystallization that decolours, take advantage of heat filtering, crystallisation by cooling 5 hours, obtain off-white color solid (R)-1-(adenine-9-yl)-2-propyl alcohol (V) 0.8g, and yield is 83.1%.
It is pointed out that above-described embodiment only is explanation technical conceive of the present invention and characteristics, its purpose is to allow the person skilled in the art can understand content of the present invention and implement according to this, can not limit the scope of the invention with this.All equivalences that spirit is done according to the present invention change or modify, within all should being encompassed in protection scope of the present invention.
Claims (6)
1. the preparation method of a tynofovir (I),
It is characterized in that described preparation method, its preparation process comprises: the 4-amino-5-nitro-6-chloropyrimide (II) of take is raw material, with (R)-propylene carbonate, carry out open loop condensation reaction generation (R)-4-[N-(2-hydroxypropyl) amido]-5-nitro-6-chloropyrimide (III), described (R)-4-[N-(2-hydroxypropyl) amido]-5-nitro-6-chloropyrimide (III) generates (R)-1-(6-chloropurine-9-yl)-2-propyl alcohol (IV) through reductive ring closure reaction, described (R)-1-(6-chloropurine-9-yl)-2-propyl alcohol (IV) generates (R)-1-(adenine-9-yl)-2-propyl alcohol (V) through ammonolysis reaction, described (R)-1-(adenine-9-yl)-2-propyl alcohol (V) makes tynofovir (I) through etherificate and hydrolysis reaction.
2. the preparation method of tynofovir (I) as claimed in claim 1, it is characterized in that: described 4-amino-5-nitro-6-chloropyrimide (II) is 1 with the molar ratio that (R)-propylene carbonate carries out the open loop condensation reaction: 0.85-2.0.
3. the preparation method of tynofovir (I) as claimed in claim 1 is characterized in that: the promotor that described 4-amino-5-nitro-6-chloropyrimide (II) and (R)-propylene carbonate carry out the open loop condensation reaction is hydride, alkali-metal carbonate, alkali-metal supercarbonate or the alkali alcoholate of metal on oxyhydroxide, basic metal or the alkali of metal on basic metal or alkali.
4. the preparation method of tynofovir (I) as claimed in claim 1, it is characterized in that: the reductive agent of described reductive ring closure reaction is zinc powder, iron powder, vat powder, hydrazine hydrate or shortening.
5. the preparation method of tynofovir (I) as claimed in claim 1, it is characterized in that: the cyclizing agent of described reductive ring closure reaction is formic acid, methyl-formiate, ethyl formate or methane amide.
6. the preparation method of tynofovir (I) as claimed in claim 1, it is characterized in that: the ammoniation agent of described ammonolysis reaction is ammoniacal liquor or liquefied ammonia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310291883.1A CN103408593B (en) | 2013-07-12 | 2013-07-12 | The preparation method of tynofovir |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310291883.1A CN103408593B (en) | 2013-07-12 | 2013-07-12 | The preparation method of tynofovir |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103408593A true CN103408593A (en) | 2013-11-27 |
| CN103408593B CN103408593B (en) | 2015-08-26 |
Family
ID=49601649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310291883.1A Expired - Fee Related CN103408593B (en) | 2013-07-12 | 2013-07-12 | The preparation method of tynofovir |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103408593B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104530050A (en) * | 2014-12-23 | 2015-04-22 | 江西富祥药业股份有限公司 | Synthesis method of tenofovir disoproxil fumarate intermediate impurity 1-amino adenine-2-propyl alcohol |
| CN104710424A (en) * | 2013-12-11 | 2015-06-17 | 河南师范大学 | Preparation method of (R)-(+)-9-(2-hydroxypropyl) adenine |
| CN105503875A (en) * | 2015-12-23 | 2016-04-20 | 江西富祥药业股份有限公司 | Synthesis method of tenofovir disoproxil fumarate intermediate impurity |
| CN108285471A (en) * | 2018-03-16 | 2018-07-17 | 安徽华昌高科药业有限公司 | A kind of preparation method of tenofovir |
| CN111961081A (en) * | 2020-10-20 | 2020-11-20 | 北京鑫开元医药科技有限公司 | Preparation method of (R) -2- (2-methoxypropyl phosphate) -adenine |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| CN101870713A (en) * | 2010-05-28 | 2010-10-27 | 杭州和素化学技术有限公司 | Industrial production process for tenofovir disoproxil fumarate |
-
2013
- 2013-07-12 CN CN201310291883.1A patent/CN103408593B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5935946A (en) * | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| CN101870713A (en) * | 2010-05-28 | 2010-10-27 | 杭州和素化学技术有限公司 | Industrial production process for tenofovir disoproxil fumarate |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104710424A (en) * | 2013-12-11 | 2015-06-17 | 河南师范大学 | Preparation method of (R)-(+)-9-(2-hydroxypropyl) adenine |
| CN104710424B (en) * | 2013-12-11 | 2017-03-01 | 河南师范大学 | (R) (+) preparation method of 9 (2 hydroxypropyl) adenine |
| CN104530050A (en) * | 2014-12-23 | 2015-04-22 | 江西富祥药业股份有限公司 | Synthesis method of tenofovir disoproxil fumarate intermediate impurity 1-amino adenine-2-propyl alcohol |
| CN105503875A (en) * | 2015-12-23 | 2016-04-20 | 江西富祥药业股份有限公司 | Synthesis method of tenofovir disoproxil fumarate intermediate impurity |
| CN105503875B (en) * | 2015-12-23 | 2017-06-20 | 江西富祥药业股份有限公司 | A kind of synthetic method of TDF intermediate impurities |
| CN108285471A (en) * | 2018-03-16 | 2018-07-17 | 安徽华昌高科药业有限公司 | A kind of preparation method of tenofovir |
| WO2019174101A1 (en) * | 2018-03-16 | 2019-09-19 | 安徽华昌高科药业有限公司 | Method for preparing tenofovir |
| CN111961081A (en) * | 2020-10-20 | 2020-11-20 | 北京鑫开元医药科技有限公司 | Preparation method of (R) -2- (2-methoxypropyl phosphate) -adenine |
| CN111961081B (en) * | 2020-10-20 | 2021-03-09 | 北京鑫开元医药科技有限公司 | Preparation method of (R) -2- (2-methoxypropyl phosphate) -adenine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103408593B (en) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103408593B (en) | The preparation method of tynofovir | |
| CN102295660A (en) | Synthetic technology of PMPA | |
| CN106458853B (en) | Method for preparing sitagliptin intermediate by asymmetric reduction method | |
| CN103408547B (en) | Preparation method of tenofovir intermediate (R)-1-(6-aminopurine-9-yl)-2-propanol (I) | |
| CN107337634B (en) | A kind of preparation method of Abbe Seeley midbody compound | |
| CN109776547A (en) | Preparation method of tofacitinib citrate | |
| CN102060876A (en) | Preparation method for tenofovir | |
| CN102367260A (en) | Synthesis method of 2-aminopyrimidine-5-boric acid | |
| CN106749259A (en) | A kind of synthetic method of cyclopenta pyrimido azoles | |
| CN104910158A (en) | 5,6,7,8-tetrahydropyrido[3,4-d] pyrimidine compound with bioactivity as well as preparation method and application thereof | |
| CN103509025A (en) | Preparation method of epinastine hydrochloride and intermediate thereof | |
| CN103396443B (en) | A kind of preparation method of tynofovir | |
| CN102267983A (en) | Sym-triazine derivative compounds containing sym-tetrazine rings and preparation method thereof | |
| CN108285471A (en) | A kind of preparation method of tenofovir | |
| CN110218189A (en) | A kind of simple and convenient process for preparing of Abbe Seeley intermediate and Abbe Seeley | |
| CN105111155A (en) | Synthesis method of tert-butyl 4,7-diazaspiro[2.5]octyl-7-formate | |
| CN105960409A (en) | Solid forms of tenofovir | |
| CN106674135A (en) | Uracil synthesizing method | |
| CN106008363B (en) | The preparation method of 2- methyl -4- amino-5-cyanopyrimidines | |
| CN102702196B (en) | Method for synthesizing 3-methyl-7-diazaindene | |
| CN112812095A (en) | Synthesis method of baroxavir pivoxil intermediate | |
| CN104098523B (en) | 1-isobutyryl-3-phenyl-Isosorbide-5-Nitrae-dihydro-1,2,4,5-tetrazine and preparation and application | |
| CN110452215A (en) | A kind of Ai Le replaces the preparation method of Buddhist nun for Buddhist nun's intermediate and Ai Le | |
| CN109651286A (en) | A kind of highly selective 4-(4- aminophenyl) morpholine -3- ketone synthetic method | |
| CN109293627B (en) | Recovery method of ketotifen intermediate mother liquor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200527 Address after: 211200 Qinhuai Road, Lishui, Nanjing Yong Yang Street, No. Avenue, No. 288 Patentee after: Nanjing Zhiwu Intelligent Technology Co.,Ltd. Address before: 215000 Jiangsu Province, Suzhou City Industrial Park Commercial Plaza Building 1 room 1305 Lianfeng Co-patentee before: Xu Xuenong Patentee before: SUZHOU MIRACPHARMA TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201030 Address after: Room 1110, Zhongtian building, No.789, north section of Yi'an Avenue, Tongling City, Anhui Province Patentee after: Anhui Chaochen Information Technology Co.,Ltd. Address before: 211200 Qinhuai Road, Lishui, Nanjing Yong Yang Street, No. Avenue, No. 288 Patentee before: Nanjing Zhiwu Intelligent Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150826 |